CERYVYN THERAPEUTICS LIMITED ADR
WKN: A2QEW7 | ISIN: US68386J2087 | Ticker-Symbol: UKJ2Siehe auch CERYVYN THERAPEUTICS LIMITED
München
31.07.26 | 08:11
0,024 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | CERYVYN THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 17.07. | CERYVYN THERAPEUTICS LIMITED: Update to Executive Chair Remuneration Arrangements | - | ASX | ||
| 13.07. | CERYVYN THERAPEUTICS LIMITED: Notification of cessation of securities - CYV | - | ASX | ||
| CERYVYN THERAPEUTICS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 10.07. | CERYVYN THERAPEUTICS LIMITED: Change of Company's Constitution | - | ASX | ||
| 08.07. | OPTHEA LIMITED: Change of Company Name, ASX Code and Registered Office | 1 | ASX | ||
| 03.07. | OPTHEA LIMITED: Results of EGM | - | ASX | ||
| 25.06. | OPTHEA LIMITED: Change of Director's Interest Notice - JL | - | ASX | ||
| 25.06. | OPTHEA LIMITED: Notification regarding unquoted securities - OPT | - | ASX | ||
| 24.06. | OPTHEA LIMITED: Becoming a substantial holder | - | ASX | ||
| 22.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 19.06. | OPTHEA LIMITED: Change of Director's Interest Notice - KC & LG | - | ASX | ||
| 18.06. | Dr Boreham's Crucible: Opthea seeks a second act with rare lung disease program | 1 | Stockhead | ||
| 18.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 18.06. | OPTHEA LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| 16.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 12.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 12.06. | OPTHEA LIMITED: Revised Webinar Details and Investor Presentation | - | ASX | ||
| 12.06. | OPTHEA LIMITED: Becoming a substantial holder | - | ASX | ||
| 10.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 09.06. | OPTHEA LIMITED: Change in substantial holding | - | ASX |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 7,700 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,330 | -9,98 % | COSCIENS Biopharma Inc. Completes Share Capital Amendment | TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), today announced the previously announced consolidation (the "Consolidation")... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 71,46 | -0,17 % | Keine Ende der Rallye in Sicht: Diese Biotechnologie-Aktie bietet für ihr Geld so viel wie kaum eine zweite! | © Foto: ZUMAPRESS.com | La Nacion - picture allianceTrotz eines enorm starken Wachstums und einer günstigen Unternehmensbewertung ist Halozyme noch immer ein Nischenwert. Das dürfte nicht mehr lange... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 4,855 | -2,02 % | AbCellera, Vertex partner on next-gen T-cell engagers | ||
| BIO-RAD LABORATORIES | 282,00 | 0,00 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| GLOW LIFETECH | 0,015 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Advances National Expansion Strategy with Quebec Commercial Partnership | Toronto, Ontario--(Newsfile Corp. - July 13, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce it has entered into an exclusive Quebec... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 2,340 | 0,00 % | BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model | Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 3,456 | +0,47 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,300 | +0,61 % | Akari Therapeutics Plc: Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics | TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 9,451 | 0,00 % | Spero Therapeutics, Inc.: Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody | Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,020 | +3,59 % | Ovid Therapeutics Inc.: Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development | Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting... ► Artikel lesen | |
| COCRYSTAL | 0,750 | +4,90 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer | BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| GEOVAX LABS | 0,704 | +3,35 % | EQS-News: GeoVax, Inc.: GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update 27.07.2026 / 22:05 CET/CEST
The issuer is... ► Artikel lesen |
Das Unternehmen CERYVYN THERAPEUTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,024 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERYVYN THERAPEUTICS LIMITED ADR finden Sie auf Wallstreet Online.